Company intelligence / Profile preview

Pharos iBio

Ownership: Private
Development stage: Other

Overview

Pharos iBio specializes in developing novel drugs for rare and refractory diseases using an AI-driven big data healthcare platform. Their lead asset has reached Phase 1 clinical trials—the first such trial in Korea using an AI-based drug development approach. The pipeline includes programs targeting FLT3, KRAS gene, FGFRs, and FAK across oncology indications such as acute myeloid leukemia and lung/ovarian cancers. The company leverages its Chemiverse System to identify new targets and compounds efficiently.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pharos iBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharos iBio.

Explore the full profile